Copyright Reports & Markets. All rights reserved.

Global Glucagon Injectable Market Growth 2022-2028

Request for Sample of this report
Buy now

1 Scope of the Report

  • 1.1 Market Introduction
  • 1.2 Years Considered
  • 1.3 Research Objectives
  • 1.4 Market Research Methodology
  • 1.5 Research Process and Data Source
  • 1.6 Economic Indicators
  • 1.7 Currency Considered

2 Executive Summary

  • 2.1 World Market Overview
    • 2.1.1 Global Glucagon Injectable Annual Sales 2017-2028
    • 2.1.2 World Current & Future Analysis for Glucagon Injectable by Geographic Region, 2017, 2022 & 2028
    • 2.1.3 World Current & Future Analysis for Glucagon Injectable by Country/Region, 2017, 2022 & 2028
  • 2.2 Glucagon Injectable Segment by Age
    • 2.2.1 Children
    • 2.2.2 Adults
  • 2.3 Glucagon Injectable Sales by Age
    • 2.3.1 Global Glucagon Injectable Sales Market Share by Age (2017-2022)
    • 2.3.2 Global Glucagon Injectable Revenue and Market Share by Age (2017-2022)
    • 2.3.3 Global Glucagon Injectable Sale Price by Age (2017-2022)
  • 2.4 Glucagon Injectable Segment by Distribution Channel
    • 2.4.1 Hospital Pharmacies
    • 2.4.2 Retail Pharmacies
    • 2.4.3 Online Pharmacies
    • 2.4.4 Others
  • 2.5 Glucagon Injectable Sales by Distribution Channel
    • 2.5.1 Global Glucagon Injectable Sale Market Share by Distribution Channel (2017-2022)
    • 2.5.2 Global Glucagon Injectable Revenue and Market Share by Distribution Channel (2017-2022)
    • 2.5.3 Global Glucagon Injectable Sale Price by Distribution Channel (2017-2022)

3 Global Glucagon Injectable by Company

  • 3.1 Global Glucagon Injectable Breakdown Data by Company
    • 3.1.1 Global Glucagon Injectable Annual Sales by Company (2020-2022)
    • 3.1.2 Global Glucagon Injectable Sales Market Share by Company (2020-2022)
  • 3.2 Global Glucagon Injectable Annual Revenue by Company (2020-2022)
    • 3.2.1 Global Glucagon Injectable Revenue by Company (2020-2022)
    • 3.2.2 Global Glucagon Injectable Revenue Market Share by Company (2020-2022)
  • 3.3 Global Glucagon Injectable Sale Price by Company
  • 3.4 Key Manufacturers Glucagon Injectable Producing Area Distribution, Sales Area, Product Type
    • 3.4.1 Key Manufacturers Glucagon Injectable Product Location Distribution
    • 3.4.2 Players Glucagon Injectable Products Offered
  • 3.5 Market Concentration Rate Analysis
    • 3.5.1 Competition Landscape Analysis
    • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
  • 3.6 New Products and Potential Entrants
  • 3.7 Mergers & Acquisitions, Expansion

4 World Historic Review for Glucagon Injectable by Geographic Region

  • 4.1 World Historic Glucagon Injectable Market Size by Geographic Region (2017-2022)
    • 4.1.1 Global Glucagon Injectable Annual Sales by Geographic Region (2017-2022)
    • 4.1.2 Global Glucagon Injectable Annual Revenue by Geographic Region
  • 4.2 World Historic Glucagon Injectable Market Size by Country/Region (2017-2022)
    • 4.2.1 Global Glucagon Injectable Annual Sales by Country/Region (2017-2022)
    • 4.2.2 Global Glucagon Injectable Annual Revenue by Country/Region
  • 4.3 Americas Glucagon Injectable Sales Growth
  • 4.4 APAC Glucagon Injectable Sales Growth
  • 4.5 Europe Glucagon Injectable Sales Growth
  • 4.6 Middle East & Africa Glucagon Injectable Sales Growth

5 Americas

  • 5.1 Americas Glucagon Injectable Sales by Country
    • 5.1.1 Americas Glucagon Injectable Sales by Country (2017-2022)
    • 5.1.2 Americas Glucagon Injectable Revenue by Country (2017-2022)
  • 5.2 Americas Glucagon Injectable Sales by Age
  • 5.3 Americas Glucagon Injectable Sales by Distribution Channel
  • 5.4 United States
  • 5.5 Canada
  • 5.6 Mexico
  • 5.7 Brazil

6 APAC

  • 6.1 APAC Glucagon Injectable Sales by Region
    • 6.1.1 APAC Glucagon Injectable Sales by Region (2017-2022)
    • 6.1.2 APAC Glucagon Injectable Revenue by Region (2017-2022)
  • 6.2 APAC Glucagon Injectable Sales by Age
  • 6.3 APAC Glucagon Injectable Sales by Distribution Channel
  • 6.4 China
  • 6.5 Japan
  • 6.6 South Korea
  • 6.7 Southeast Asia
  • 6.8 India
  • 6.9 Australia
  • 6.10 China Taiwan

7 Europe

  • 7.1 Europe Glucagon Injectable by Country
    • 7.1.1 Europe Glucagon Injectable Sales by Country (2017-2022)
    • 7.1.2 Europe Glucagon Injectable Revenue by Country (2017-2022)
  • 7.2 Europe Glucagon Injectable Sales by Age
  • 7.3 Europe Glucagon Injectable Sales by Distribution Channel
  • 7.4 Germany
  • 7.5 France
  • 7.6 UK
  • 7.7 Italy
  • 7.8 Russia

8 Middle East & Africa

  • 8.1 Middle East & Africa Glucagon Injectable by Country
    • 8.1.1 Middle East & Africa Glucagon Injectable Sales by Country (2017-2022)
    • 8.1.2 Middle East & Africa Glucagon Injectable Revenue by Country (2017-2022)
  • 8.2 Middle East & Africa Glucagon Injectable Sales by Age
  • 8.3 Middle East & Africa Glucagon Injectable Sales by Distribution Channel
  • 8.4 Egypt
  • 8.5 South Africa
  • 8.6 Israel
  • 8.7 Turkey
  • 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities
  • 9.2 Market Challenges & Risks
  • 9.3 Industry Trends

10 Manufacturing Cost Structure Analysis

  • 10.1 Raw Material and Suppliers
  • 10.2 Manufacturing Cost Structure Analysis of Glucagon Injectable
  • 10.3 Manufacturing Process Analysis of Glucagon Injectable
  • 10.4 Industry Chain Structure of Glucagon Injectable

11 Marketing, Distributors and Customer

  • 11.1 Sales Channel
    • 11.1.1 Direct Channels
    • 11.1.2 Indirect Channels
  • 11.2 Glucagon Injectable Distributors
  • 11.3 Glucagon Injectable Customer

12 World Forecast Review for Glucagon Injectable by Geographic Region

  • 12.1 Global Glucagon Injectable Market Size Forecast by Region
    • 12.1.1 Global Glucagon Injectable Forecast by Region (2023-2028)
    • 12.1.2 Global Glucagon Injectable Annual Revenue Forecast by Region (2023-2028)
  • 12.2 Americas Forecast by Country
  • 12.3 APAC Forecast by Region
  • 12.4 Europe Forecast by Country
  • 12.5 Middle East & Africa Forecast by Country
  • 12.6 Global Glucagon Injectable Forecast by Age
  • 12.7 Global Glucagon Injectable Forecast by Distribution Channel

13 Key Players Analysis

  • 13.1 Fresenius SE & Co. KGaA
    • 13.1.1 Fresenius SE & Co. KGaA Company Information
    • 13.1.2 Fresenius SE & Co. KGaA Glucagon Injectable Product Offered
    • 13.1.3 Fresenius SE & Co. KGaA Glucagon Injectable Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.1.4 Fresenius SE & Co. KGaA Main Business Overview
    • 13.1.5 Fresenius SE & Co. KGaA Latest Developments
  • 13.2 Xeris Pharmaceuticals Inc
    • 13.2.1 Xeris Pharmaceuticals Inc Company Information
    • 13.2.2 Xeris Pharmaceuticals Inc Glucagon Injectable Product Offered
    • 13.2.3 Xeris Pharmaceuticals Inc Glucagon Injectable Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.2.4 Xeris Pharmaceuticals Inc Main Business Overview
    • 13.2.5 Xeris Pharmaceuticals Inc Latest Developments
  • 13.3 Novo Nordisk A/S
    • 13.3.1 Novo Nordisk A/S Company Information
    • 13.3.2 Novo Nordisk A/S Glucagon Injectable Product Offered
    • 13.3.3 Novo Nordisk A/S Glucagon Injectable Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.3.4 Novo Nordisk A/S Main Business Overview
    • 13.3.5 Novo Nordisk A/S Latest Developments
  • 13.4 ILS.Inc
    • 13.4.1 ILS.Inc Company Information
    • 13.4.2 ILS.Inc Glucagon Injectable Product Offered
    • 13.4.3 ILS.Inc Glucagon Injectable Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.4.4 ILS.Inc Main Business Overview
    • 13.4.5 ILS.Inc Latest Developments
  • 13.5 Amphastar Pharmaceuticals Inc.
    • 13.5.1 Amphastar Pharmaceuticals Inc. Company Information
    • 13.5.2 Amphastar Pharmaceuticals Inc. Glucagon Injectable Product Offered
    • 13.5.3 Amphastar Pharmaceuticals Inc. Glucagon Injectable Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.5.4 Amphastar Pharmaceuticals Inc. Main Business Overview
    • 13.5.5 Amphastar Pharmaceuticals Inc. Latest Developments
  • 13.6 Lilly USA, LLC
    • 13.6.1 Lilly USA, LLC Company Information
    • 13.6.2 Lilly USA, LLC Glucagon Injectable Product Offered
    • 13.6.3 Lilly USA, LLC Glucagon Injectable Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.6.4 Lilly USA, LLC Main Business Overview
    • 13.6.5 Lilly USA, LLC Latest Developments
  • 13.7 Zealand Pharma A/S.
    • 13.7.1 Zealand Pharma A/S. Company Information
    • 13.7.2 Zealand Pharma A/S. Glucagon Injectable Product Offered
    • 13.7.3 Zealand Pharma A/S. Glucagon Injectable Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.7.4 Zealand Pharma A/S. Main Business Overview
    • 13.7.5 Zealand Pharma A/S. Latest Developments
  • 13.8 Avalon Pharma Pvt. Ltd.
    • 13.8.1 Avalon Pharma Pvt. Ltd. Company Information
    • 13.8.2 Avalon Pharma Pvt. Ltd. Glucagon Injectable Product Offered
    • 13.8.3 Avalon Pharma Pvt. Ltd. Glucagon Injectable Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.8.4 Avalon Pharma Pvt. Ltd. Main Business Overview
    • 13.8.5 Avalon Pharma Pvt. Ltd. Latest Developments

14 Research Findings and Conclusion

As the global economy mends, the 2021 growth of Glucagon Injectable will have significant change from previous year. According to our (LP Information) latest study, the global Glucagon Injectable market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Glucagon Injectable market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.
The United States Glucagon Injectable market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Glucagon Injectable market, reaching US$ million by the year 2028. As for the Europe Glucagon Injectable landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Glucagon Injectable players cover Fresenius SE & Co. KGaA, Xeris Pharmaceuticals Inc, Novo Nordisk A/S, and ILS.Inc, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Glucagon Injectable market by product type, application, key manufacturers and key regions and countries.
Segmentation by age: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
Children
Adults
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
Fresenius SE & Co. KGaA
Xeris Pharmaceuticals Inc
Novo Nordisk A/S
ILS.Inc
Amphastar Pharmaceuticals Inc.
Lilly USA, LLC
Zealand Pharma A/S.
Avalon Pharma Pvt. Ltd.
Buy now